MBX Biosciences News

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...

BenzingaNov 18 08:19 ET

Express News | Mbx Biosciences : Look Forward to Sharing Full-Topline Results of Mbx 1416 Program in Early January 2025

ReutersNov 18 08:03 ET

Express News | Mbx Biosciences Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia

ReutersNov 18 08:00 ET

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

GlobeNewswireNov 18 08:00 ET

MBX Biosciences | 10-Q: Quarterly report

SECNov 7 08:33 ET · Announcements

MBX Biosciences | 8-K: MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

SECNov 7 08:13 ET

Express News | Mbx Biosciences: Strong Cash Position, With $277.1 Mln Expected to Support Operations Into Mid-2027

ReutersNov 7 08:09 ET

MBX Biosciences Reports Q3 EPS ($2.78), Consensus ($2.72)

TipRanksNov 7 08:08 ET

MBX Biosciences 3Q Research and Development Expenses $16.7M >MBX

Dow JonesNov 7 08:07 ET

Earnings Flash (MBX) MBX BIOSCIENCES Posts Q3 Loss $-2.78 Per Share

MT NewswiresNov 7 08:04 ET

Express News | Mbx Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

ReutersNov 7 08:00 ET

Press Release: MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Dow JonesNov 7 08:00 ET

MBX Biosciences to Participate in Upcoming November Investor Conferences

GlobeNewswireOct 28 08:00 ET

MBX Bio Drops Despite Bullish Views on Street

Seeking AlphaOct 8 15:15 ET

MBX Biosciences Price Target Announced at $35.00/Share by Jefferies

Dow JonesOct 8 14:29 ET · Ratings

Express News | Mbx Biosciences Shares Down 5.1%; Brokerages Initiate Coverage With Bullish Ratings

ReutersOct 8 11:18 ET

MBX Biosciences Earns Buy Rating at Three Investment Firms

InvestingOct 8 10:36 ET

A Quick Look at Today's Ratings for MBX Biosciences(MBX.US), With a Forecast Between $30 to $44

Moomoo NewsOct 8 09:00 ET · Ratings

MBX Biosciences Analyst Ratings

BenzingaOct 8 05:54 ET · Ratings

Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Zenas BioPharma, Inc. (ZBIO)

TipRanksOct 8 05:30 ET · Ratings